Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type; [! N* s! S5 E" ]! I! V: V, c
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 , }7 J: r" W, m$ O
+ Author Affiliations
$ u0 H% U7 C9 h
! ^, ~+ N5 _* C1 a S1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan , V" H, I4 K- G: G! l
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ Y- u3 t. y$ |" t1 E% {% M# p3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " \) C( u2 \! E- q
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 6 \! p: w2 `& o; @
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
( O6 f5 B2 C' @' Y) `$ s6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ; i5 Z" N2 k8 ~
7Kinki University School of Medicine, Osaka 589-8511, Japan + E: o+ ]0 r+ L# h
8Izumi Municipal Hospital, Osaka 594-0071, Japan
# a/ B# k% X2 V3 b: ]( O9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
0 i, S8 s/ N% t% A, w! g5 yCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 5 H0 Y% e2 x% N9 w: z
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. " Z) k$ ]: b/ w! P4 _; X
4 x& T- y" O8 k# ]' C
|